Uncategorized

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is ‘sole muscarinic winner.’

  Las casas de apuestas en línea han revolucionado la forma en que muchas personas disfrutan del entretenimiento. Ahora, con solo unos clics, es posible acceder a miles de juegos, apuestas deportivas y promociones exclusivas desde cualquier lugar. Sin embargo, para lograr el éx …

Boston Scientific announced the acquisition in January, but the review timeline dragged on after the Federal Trade Commission requested more information.

A facility in Lexington will close, and smaller numbers of people will be laid off at plants in Cambridge and Plainville.

Bluebird has just two quarters until it’s out of cash. Executives are looking for financing to extend that runway to a projected breakeven point before the end of 2025, with analysts worried they won’t make it.

Eyenovia’s stock craters to its lowest point in its six-year lifespan as a public company following the biotech’s termination of its lead program in pediatric progressive myopia due to lack of efficacy.

The Franklin, Tennessee-based operator has not purchased a hospital in years. That may soon change as CHS’ margins improve.

BMS has so far been on a winning streak in the contingent value right cases, which allege that the pharma intentionally delayed regulatory activities for Breyanzi in order to avoid a $6.4 billion payout to Celgene shareholders.

Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.

Trump’s HHS pick, Robert F. Kennedy Jr., is an anti-vaccine campaigner who has previously said that he plans to gut the FDA on allegations of corruption and reduce the NIH’s headcount.